128 related articles for article (PubMed ID: 35595567)
1. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations.
Hamad A; Eskander MF; Shen C; Bhattacharyya O; Fisher JL; Oppong BA; Obeng-Gyasi S; Tsung A
Surgery; 2022 Sep; 172(3):982-988. PubMed ID: 35595567
[TBL] [Abstract][Full Text] [Related]
2. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population.
Corey L; Cote ML; Ruterbusch JJ; Vezina A; Winer I
Am J Obstet Gynecol; 2022 Apr; 226(4):541.e1-541.e13. PubMed ID: 34736911
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database.
Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A
Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154
[TBL] [Abstract][Full Text] [Related]
4. Sociodemographic Disparities in the Receipt of Adjuvant Chemotherapy Among Patients With Resected Stage I-III Pancreatic Adenocarcinoma.
Sanford NN; Aguilera TA; Folkert MR; Ahn C; Mahal BA; Zeh H; Beg MS; Mansour J; Sher DJ
J Natl Compr Canc Netw; 2019 Nov; 17(11):1292-1300. PubMed ID: 31693987
[TBL] [Abstract][Full Text] [Related]
5. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
[TBL] [Abstract][Full Text] [Related]
6. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma.
Anteby R; Blaszkowsky LS; Hong TS; Qadan M
Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536
[TBL] [Abstract][Full Text] [Related]
7. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
[TBL] [Abstract][Full Text] [Related]
8. A national evaluation of adjuvant chemotherapy in pT4N0M0 colon cancer from the National Cancer Database.
Reif de Paula T; Keller DS
J Natl Cancer Inst; 2023 Dec; 115(12):1616-1625. PubMed ID: 37584736
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head.
Lutfi W; Talamonti MS; Kantor O; Wang CH; Liederbach E; Stocker SJ; Bentrem DJ; Roggin KK; Winchester DJ; Marsh R; Prinz RA; Baker MS
Surgery; 2016 Sep; 160(3):714-24. PubMed ID: 27422328
[TBL] [Abstract][Full Text] [Related]
10. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer.
Hao S; Mitsakos A; Irish W; Tuttle-Newhall JE; Parikh AA; Snyder RA
J Surg Oncol; 2022 Aug; 126(2):302-313. PubMed ID: 35315932
[TBL] [Abstract][Full Text] [Related]
11. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.
Parmar AD; Vargas GM; Tamirisa NP; Sheffield KM; Riall TS
Surgery; 2014 Aug; 156(2):280-9. PubMed ID: 24851723
[TBL] [Abstract][Full Text] [Related]
12. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
Merkow RP; Bilimoria KY; Tomlinson JS; Paruch JL; Fleming JB; Talamonti MS; Ko CY; Bentrem DJ
Ann Surg; 2014 Aug; 260(2):372-7. PubMed ID: 24374509
[TBL] [Abstract][Full Text] [Related]
13. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma.
Boyd CA; Benarroch-Gampel J; Sheffield KM; Han Y; Kuo YF; Riall TS
Surgery; 2012 Sep; 152(3):403-13. PubMed ID: 22938900
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant
Hashmi A; Kozick Z; Fluck M; Hunsinger MA; Wild J; Arora TK; Shabahang MM; Blansfield JA
Am Surg; 2018 Sep; 84(9):1439-1445. PubMed ID: 30268172
[TBL] [Abstract][Full Text] [Related]
16. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
[TBL] [Abstract][Full Text] [Related]
17. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.
Ma SJ; Oladeru OT; Miccio JA; Iovoli AJ; Hermann GM; Singh AK
JAMA Netw Open; 2019 Aug; 2(8):e199126. PubMed ID: 31411712
[TBL] [Abstract][Full Text] [Related]
18. Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.
Valdera FA; O'Shea AE; Smolinsky TR; Carpenter EL; Adams AA; McCarthy PM; Tiwari A; Chick RC; Kemp-Bohan PM; Van Decar S; Thomas KK; Bader JO; Peoples GE; Clifton GT; Stojadinovic A; Nelson DW; Vreeland TJ
J Surg Oncol; 2024 Feb; 129(2):244-253. PubMed ID: 37800378
[TBL] [Abstract][Full Text] [Related]
19. The treatment sequence may matter in patients undergoing pancreatoduodenectomy for early stage pancreatic cancer in the era of modern chemotherapy.
Watson MD; Thompson KJ; Musselwhite LW; Hwang JJ; Baker EH; Martinie JB; Vrochides D; Iannitti DA; Ocuin LM
Am J Surg; 2021 Jul; 222(1):159-166. PubMed ID: 33121658
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer.
Evans D; Ghassemi N; Hajibandeh S; Hajibandeh S; Romman S; Laing RW; Durkin D; Athwal TS
Surgery; 2024 Jun; 175(6):1470-1479. PubMed ID: 38160086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
